NEW YORK: ImpediMed, the Australian medical device company, has named Russo Partners as its US agency in order to support a campaign geared at educating breast surgeons on the “lymphedema index.”
The index is a measure of a patient's likelihood to develop lymphedema, a condition in which fluid builds up in the arms of breast cancer patients. The US work will focus on three upcoming crucial events for the company, according to David Schull, president of Russo Partners.
First, the American Society ...